Biohaven Ltd.
Organization details
- Legal name
- Biohaven Ltd.
- Former names
- Biohaven Research Ltd.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Virgin Islands, British
- Headquarters city
- New Haven
- Headquarters state / province
- Connecticut
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BHVN
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001935979
Board of directors
-
Gregory Bailey · DirectorSince 2023
-
Irina Antonijevic · DirectorSince 2023
-
John W. Childs · DirectorSince 2023
-
John Yetimoglu · DirectorSince 2026
-
Julia P. Gregory · DirectorSince 2023
-
Kishan Mehta · DirectorSince 2023
- Since 2023
-
Robert J. Hugin · DirectorSince 2023
-
Vlad Coric · Director · Chief Executive OfficerSince 2023
Chief executives
Board connections
7 of this board's directors also sit on 10 other boards. 9 are in the same sector.
-
Veradermics Incorporated Same sectorvia John W. Childs and Vlad Coric
-
Avalo Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
-
Benitec Biopharma Inc. Same sectorvia Kishan Mehta
- via Robert J. Hugin
-
Collegium Pharmaceutical Inc. Same sectorvia Michael Thomas Heffernan
-
Nurix Therapeutics Inc. Same sectorvia Julia P. Gregory
-
Royalty Pharma plc Same sectorvia Vlad Coric
-
Serina Therapeutics Inc. Same sectorvia Gregory Bailey
-
Trevi Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
-
enGene Therapeutics Inc. Same sectorvia Michael Thomas Heffernan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $33,144,833
- 5 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 17, 2026 | Kishan Mehta Director | Gift | −17,342 | — | — |
| Mar 17, 2026 | Kishan Mehta Director | Gift | +17,342 | — | — |
| Jan 5, 2026 | Gentile Kimberly Officer (SVP, Clinical Operations) | Option exercise | +3,750 | — | — |
| Jan 5, 2026 | Buten Matthew Officer (Chief Financial Officer) | Option exercise | +4,250 | — | — |
| Jan 5, 2026 | Vlad Coric Director, Officer (Chief Executive Officer) | Option exercise | +14,250 | — | — |
| Jan 5, 2026 | Car Bruce Officer (Chief Scientific Officer) | Option exercise | +4,750 | — | — |
| Jan 5, 2026 | Clark George C. Officer (VP, Chief Accounting Officer) | Option exercise | +2,500 | — | — |
| Jan 5, 2026 | Gentile Kimberly Officer (SVP, Clinical Operations) | Shares withheld for tax | −1,956 | $9.93 | $19,423 |
| Jan 5, 2026 | Buten Matthew Officer (Chief Financial Officer) | Shares withheld for tax | −2,594 | $9.93 | $25,758 |
| Jan 5, 2026 | Vlad Coric Director, Officer (Chief Executive Officer) | Shares withheld for tax | −7,430 | $9.93 | $73,780 |
| Jan 5, 2026 | Car Bruce Officer (Chief Scientific Officer) | Shares withheld for tax | −2,381 | $9.93 | $23,643 |
| Jan 5, 2026 | Clark George C. Officer (VP, Chief Accounting Officer) | Shares withheld for tax | −1,117 | $9.93 | $11,092 |
| Nov 17, 2025 | Clark George C. Officer (VP, Chief Accounting Officer) | Open-market purchase | +17,000 | $8.52 | $144,840 |
| Nov 13, 2025 | Gregory Bailey Director | Open-market purchase | +400,000 | $7.50 | $3,000,000 |
| Nov 13, 2025 | John W. Childs Director | Open-market purchase | +3,333,333 | $7.50 | $24,999,998 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Biohaven Ltd.
Who is the CEO of Biohaven Ltd.?
Vlad Coric is Biohaven Ltd.'s Chief Executive Officer.
How many directors are on Biohaven Ltd.'s board?
Biohaven Ltd.'s board has 9 directors: Gregory Bailey, Irina Antonijevic, John W. Childs, John Yetimoglu, Julia P. Gregory, Kishan Mehta, Michael Thomas Heffernan, Robert J. Hugin and Vlad Coric.
Are Biohaven Ltd. insiders buying or selling shares?
Over the last 12 months, Biohaven Ltd. insiders bought $33.1 million of shares in 5 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="biohaven-ltd"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.